AFFILIATIONS
1 Harvard Medical School, Boston, Massachusetts, United States
2 Harvard Medical School, Boston, Massachusetts, United States, Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States
3 Harvard Medical School, Boston, Massachusetts, United States, Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States
4 Harvard Medical School, Boston, Massachusetts, United States, Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States
5 Harvard Medical School, Boston, Massachusetts, United States, Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States
6 Harvard Medical School, Boston, Massachusetts, United States, Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States
7 Harvard Medical School, Boston, Massachusetts, United States, Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States
8 Harvard Medical School, Boston, Massachusetts, United States, Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States
9 Harvard Medical School, Boston, Massachusetts, United States, Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States
10 Harvard Medical School, Boston, Massachusetts, United States, Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States
11 Harvard Medical School, Boston, Massachusetts, United States, Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States
12 Harvard Medical School, Boston, Massachusetts, United States, Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States
13 Harvard Medical School, Boston, Massachusetts, United States, Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States
14 Harvard Medical School, Boston, Massachusetts, United States, Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States
15 Harvard Medical School, Boston, Massachusetts, United States, Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States
16 Harvard Medical School, Boston, Massachusetts, United States, Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States
17 Harvard Medical School, Boston, Massachusetts, United States, Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States
18 Harvard Medical School, Boston, Massachusetts, United States, Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States
19 Harvard Medical School, Boston, Massachusetts, United States, Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States
20 Harvard Medical School, Boston, Massachusetts, United States, Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States
21 Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts, United States
22 Harvard Medical School, Boston, Massachusetts, United States, Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States
ABSTRACT
Background: Patients with DR CLL refractory to both covalent Bruton tyrosine kinase inhibitors (cBTKis) and BCL2 inhibitors (BCL2is) have poorer outcomes than DE patients. It remains unknown whether the line of therapy and the CON vs. SEQ exposure to BTKi/BCL2i influence the outcome of DR and DE CLL.
Methods: In this retrospective analysis, we applied three subgroup definitions based on: 1) treatment sensitivity (DR vs. DE), 2) lines of therapy (treatment-naïve [TN] vs. relapsed/refractory [R/R]), and 3) treatment types (CON vs. SEQ). Patients with DR CLL had progressive disease (PD) during active treatment with cBTKi/BCL2i or within 6 months of treatment cessation, while those with DE CLL did not have any PD or PD on one targeted agent. CON exposure referred to the combination of cBTKi/BCL2i with or without anti-CD20 monoclonal antibody. SEQ exposure referred to separate treatment courses without intervening therapy between the two classes. The landmark timepoint was the start date of combination therapy for the CON group or the first targeted class for the SEQ group. We assessed overall survival (OS); time to next treatment or death (TTNT-D), defined as initiation of the next CLL therapy or death from any cause; and time to next treatment mechanism or death (TTM-D), with events defined as initiation of CLL therapy with a mechanism of action different from cBTKi/BCL2i or death. We used the Kaplan-Meier method, Cox regression, and inverse probability of treatment weighting (IPTW) to control for known prognostic markers of CLL (age, TP53 aberration, IGHV, sex, complex karyotype) using R version 4.6.1.
Results: Of 1,058 patients registered in the institutional database, 149 patients with CLL were exposed to both cBTKi/BCL2i. 26 (17%) were DR, and 123 (83%) were DE. 77 (52%) received CON cBTKi/BCL2i, and 72 (48%) had SEQ exposure. 67 (45%) were TN, and 82 (55%) were R/R before ever receiving a cBTKi/BCL2i. In the entire cohort, the median age was 67 years, and 86% had unmutated IGHV (100% in DR, 82% in DE). TP53 aberrations were more frequently found in DR vs. DE (73% vs 43%; p=.009) and similar in SEQ vs. CON (56% vs. 42%) and R/R vs. TN (44% vs. 55%). BTK mutations were enriched in DR vs. DE (58% vs. 10%), SEQ vs. CON (41% vs. 5%), and R/R vs. TN groups (32% vs. 4%; all p<.001).
With a median follow-up of 9.5 years from CLL diagnosis and 4.7 years from the landmark, 39 (26%) patients had died. PD (44% of any deaths) was the most common cause of death, followed by infection (18%). OS was inferior with DR than DE disease (hazard ratio [HR] 3.7, 95% confidence interval [CI] 1.7-7.8), and similar between R/R and TN (HR 1.43; CI 95% 0.51-2.48). PD was more frequently reported from DR vs. DE (96% vs. 23%), and R/R vs. TN CLL (45% vs. 24%). Richter transformation was also found more frequently in DR and R/R disease. DR CLL during CON BTKi/BCL2i therapy was rare, found in only 1 patient in the TN setting and 5 in R/R.
Given small numbers of patients in each subgroup and potential bias in patient and treatment selection, we conducted descriptive analyses of outcomes in CON and SEQ groups and separately analyzed TN and R/R disease. In TN patients, the rates of 5-year OS, TTNT-D, and TTM-D were 88% (95% CI 68-96%), 65% (95% CI 44-80%), and 57% (95% CI 36-74%), respectively, in the SEQ group, and 97% (95% CI 82-100%), 74% (95% CI 50-88%), and 95% (95% CI 80-99%), respectively, in the CON group. Although DR CLL was a small subgroup (n=7 or 10% of TN), it had a distinctly poor outcome with a 5-year OS of 71% (95% CI 26-92%) compared to DE CLL at 97% (95% CI 87-99%). In R/R patients, the rates of 5-year OS, TTNT-D, and TTM-D were 78% (95% CI 63-87%), 71% (95% CI 56-82%), and 56% (95% CI 40-69%), respectively, in the SEQ group, and 81% (95% CI 54-93%), 35% (95% CI 2-77%), and 55% (95% CI 9-86%), respectively, in the CON group. DR disease was found in 19 (23%) patients with R/R CLL and was associated with poor outcome, with a shorter 5-year OS in DR (50% [95% CI 26-70%]) compared to DE (88%, 95% CI 72-94%), regardless of how BTKi/BCL2i was given (CON vs SEQ).
Conclusions: DR CLL was associated with markedly inferior survival regardless of concurrent or sequential exposure to targeted therapy or the line of therapy. Our data suggest the need for prospective comparison of sequential and combination approaches to optimize long-term outcomes for pts with CLL treated with cBTKi/BCL2i-based therapy.